MyODP News Online

CDC Releases Interim Clinical Considerations for Use of mRNA COVID-19 Vaccines Currently Authorized in the United States

The CDC co branded logo with US Department of health and human services. Background is ocean blue with an minimalist illustration of an eagle in the DHS logoThe Centers for Disease Control and Prevention have released interim recommendations for the use of both the Moderna and Pfizer COVID-19 vaccines published by the Advisory Committee on Immunization Practices. The recommendations review the FDA authorized mRNA vaccines and their proper administration at this time. 

Per the source of the new clinical recommendations, the sites states: 

"These interim CDC clinical considerations are informed by data submitted to the Food and Drug Administration for Emergency Use Authorization (EUA) of the vaccines, other data sources, general best practice guidelines for immunization, and expert opinion. These considerations for mRNA vaccines only apply to the currently authorized vaccine products in the United States (i.e., Pfizer-BioNTech and Moderna COVID-19 vaccines). Considerations will be updated as additional information becomes available or if additional vaccine products are authorized."

Read the Interim Clinical Considerations document here.